PubMed Health⌕ Search

PubMed · 4050815

Complying with workers' right-to-know legislation.

Abstract

The development of a manual of drug monographs about the handling of antineoplastic agents that complies with the Minnesota Right-to-Know Act is described. The Occupational Safety and Health Administration (OSHA) regulations require manufacturers to provide employees with information about dangerous substances they handle as part of their jobs. OSHA regulations exclude the health-care job sector and drugs, but many states have passed workers' right-to-know acts that include pharmacies. Under the Minnesota Workers' Right-to-Know Act, many antineoplastic drugs are classified as hazardous substances. The Minnesota law applies to all employers, who must provide information and training to all employees who handle these agents. At Midway Hospital in St. Paul, a manual containing information about antineoplastic drugs was developed by the pharmacy department to comply with Minnesota law. The drug monographs were written by pharmacy personnel using information received from drug companies and published articles. The manual was used to teach technicians as well as members of the oncology-unit nursing staff and nursing personnel at a nearby clinic about handling antineoplastic agents. Pharmacy directors in states with right-to-know laws must determine whether the health-care job sector and drugs are covered and, if so, implement policies to teach employees about the handling of these toxic agents.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

M J Knoeck, W B Wadd, R M Giese. 1985. Complying with workers' right-to-know legislation.. https://pubmed.ncbi.nlm.nih.gov/4050815/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Deep generative neural network for accurate drug response imputation.

Drug response differs substantially in cancer patients due to inter- and intra-tumor heterogeneity. Particularly, transcriptome context, especially tumor microenvironment, has been shown playing a significant role in shaping the actual treatment outcome. In this study, we develop a deep variational autoencoder (VAE) model to compress thousands of genes into latent vectors in a low-dimensional space. We then demonstrate that these encoded vectors could accurately impute drug response, outperform standard signature-gene based approaches, and appropriately control the overfitting problem. We apply rigorous quality assessment and validation, including assessing the impact of cell line lineage, cross-validation, cross-panel evaluation, and application in independent clinical data sets, to warrant the accuracy of the imputed drug response in both cell lines and cancer samples. Specifically, the expression-regulated component (EReX) of the observed drug response achieves high correlation across panels. Using the well-trained models, we impute drug response of The Cancer Genome Atlas data and investigate the features and signatures associated with the imputed drug response, including cell line origins, somatic mutations and tumor mutation burdens, tumor microenvironment, and confounding factors. In summary, our deep learning method and the results are useful for the study of signatures and markers of drug response.

Antineoplastic Agents↗

Favorable response of intraommaya topotecan for leptomeningeal metastasis of neuroblastoma after intravenous route failure.

A 3-year-old male, diagnosed with stage 4 neuroblastoma, developed recurrent leptomeningeal metastasis after multi-modality treatment including multi-agent chemotherapy, surgery, high dose chemotherapy plus stem cell rescue, cis-retinoic acid and intravenous (IV) topotecan. He then received intraommaya (IO) topotecan three times weekly (maximum dose; 0.4 mg). A complete response was achieved by a resolution of malignant cells in cerebrospinal fluid and resolution leptomeningeal enhancement by brain MRI. Treatment toxicities included low-grade fever and minimal headache. The duration of treatment response from IO topotecan was 18 weeks. The survival time from CNS recurrence in this patient was 13 months. We suggest IO topotecan be considered for neoplastic meningitis of tumors with known sensitivity to topotecan.

Antineoplastic Agents↗

Mobilization of Ph chromosome-negative peripheral blood stem cells in a child with chronic myeloid leukemia after imatinib-induced complete molecular remission.

Chronic myelogenous leukemia (CML) is rare in the pediatric population. Allogeneic stem cell transplant remains the only curative therapy; however, identifying a fully matched donor is not always possible. Imatinib mesylate has been shown to induce hematologic and cytogenetic response in adults and children with CML. We describe a child who achieved molecular remission with imatinib mesylate. BCR-ABL negative peripheral blood stem cells (PBSC) were successfully collected after mobilization with filgrastim.

Antineoplastic Agents↗